MPO Inhibitor A_Zeneca for HFpEF

Status:
Recruiting

Trial end date:
2022-04-21

Target enrollment:

Participant gender:

Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.

Phase 1/Phase 2

Mayo Clinic